U.S. Markets open in 3 hrs 22 mins
  • S&P Futures

    -42.50 (-1.16%)
  • Dow Futures

    -274.00 (-0.94%)
  • Nasdaq Futures

    -178.50 (-1.57%)
  • Russell 2000 Futures

    -16.80 (-1.01%)
  • Crude Oil

    -0.19 (-0.24%)
  • Gold

    -12.50 (-0.76%)
  • Silver

    -0.41 (-2.22%)

    -0.0045 (-0.4681%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +2.31 (+7.16%)

    -0.0101 (-0.9365%)

    +0.0140 (+0.0097%)

    -1,547.33 (-7.66%)
  • CMC Crypto 200

    -31.42 (-6.84%)
  • FTSE 100

    -132.72 (-1.90%)
  • Nikkei 225

    -397.89 (-1.50%)

Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates

·3 min read

This week, the FDA approved AstraZeneca’s AZN PD-L1 inhibitor, Imfinzi as a combination regimen for treating advanced metastatic biliary tract cancer and granted Breakthrough Therapy Designation to Pfizer’s PFE vaccine candidate to prevent Group B Streptococcus (GBS) infections. The regulatory body also said that it will conduct an advisory panel meeting to review GSK’s GSK regulatory filing seeking approval for its pipeline candidate, daprodustat.

Recap of the Week’s Most Important Stories

FDA Nod to AstraZeneca’s Imfinzi for a New Indication: The FDA approved AstraZeneca’s PD-L1 inhibitor, Imfinzi plus chemotherapy for treating locally advanced or metastatic biliary tract cancer (BTC). Imfinzi is presently approved for unresectable, stage III non-small-cell lung cancer (NSCLC) and first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Imfinzi plus chemotherapy (gemcitabine plus cisplatin) became the first immunotherapy regimen to be approved for BTC. The approval was based on data from the TOPAZ-1 phase III study, which showed that Imfinzi plus chemotherapy led to a 20% reduction in the risk of death versus chemotherapy alone.

FDA to Hold Advisory Panel Meeting for GSK’s Daprodustat NDA: The FDA informed GSK that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new drug application (NDA) seeking approval of daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for anemia associated with chronic renal disease (CKD). The date of the advisory committee meeting is set for Oct 26, 2022. The FDA accepted GSK’s NDA for daprodustat in April and granted a standard review to the same. A decision is expected on Feb 1, 2023. A marketing authorization application (MAA) for daprodustat is also under review in Europe. Daprodustat is only approved in Japan as Duvroq for anemia associated with CKD.

FDA Breakthrough Tag for Pfizer’s Streptococcus Vaccine Candidate: The FDA granted Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus (GBS) vaccine candidate, GBS6, for the prevention of invasive GBS infections due to vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. GBS6 is being evaluated in the phase II study in healthy pregnant women aged 18 to 40 years in South Africa, the United Kingdom, and the United States. Interim data from this study formed the basis for the BTD tag.

The NYSE ARCA Pharmaceutical Index rose 0.6% in the last five trading sessions.

Large Cap Pharmaceuticals Industry 5YR % Return

Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return

Large Cap Pharmaceuticals Industry 5YR % Return

Here’s how the eight major stocks performed in the last five trading sessions.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

In the last five trading sessions, Roche rose the most (3.6%) while AstraZeneca declined the most (2.4%).

In the past six months, Lilly has gained the highest (18.6%) while Roche declined the most (11%).

(See the last pharma stock roundup here: FDA Authorization of Omicron Boosters, SNY’s Xenpozyme & More

What's Next in the Pharma World?

Watch out for regular pipeline and regulatory updates next week.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research